decitabine + NY-ESO-1 peptide vaccine + pegylated liposomal doxorubicin hydrochloride + sargramostim + incomplete Freund's adjuvant
Phase 1CompletedDevelopment Stage
Recurrent Fallopian Tube Cancer
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Apr 1, 2009 → Jun 1, 2013
About decitabine + NY-ESO-1 peptide vaccine + pegylated liposomal doxorubicin hydrochloride + sargramostim + incomplete Freund's adjuvant
decitabine + NY-ESO-1 peptide vaccine + pegylated liposomal doxorubicin hydrochloride + sargramostim + incomplete Freund's adjuvant is a phase 1 stage product being developed by Eisai for Recurrent Fallopian Tube Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01673217. Target conditions include Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Fallopian Tube Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01673217 | Phase 1 | Completed |
Competing Products
20 competing products in Recurrent Fallopian Tube Cancer